Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Izotropic Corp. (IZO) has engaged clinical research organization ICON plc to help prepare for its upcoming clinical study and submission for market authorization in the U.S.
  • ICON’s medical device team will support multiple aspects of Izotropic’s clinical research study including contracting, start-up, data collection and analysis, and report writing for FDA submission
  • Izotropic Corp. is the only publicly traded company commercializing a dedicated breast CT imaging platform for the more accurate detection and diagnosis of breast cancers
  • Izotropic (IZO) is up 7.69 per cent, trading at C$0.42 at 11:45 am ET

Izotropic Corp. (IZO) has engaged ICON plc to help prepare for its upcoming clinical study and submission for market authorization in the U.S.

Clinical research organization ICON’s medical device team will support multiple aspects of Izotropic’s clinical research study, including contracting, start-up, data collection and analysis, and report writing for FDA submission.

Izotropic’s CEO, Dr. John McGraw, stated that Engaging ICON means that the company is confidently moving forward with its business plans to bring IzoView, its dedicated breast CT imaging platform, to market efficiently.

“We plan to run a multi-site study with leading U.S. hospitals which will help to expedite patient recruitment and broadens the clinical experience with IzoView. When operating a multi-site study, it is critical that the same set of processes and procedures from start to finish are followed at each site for every patient to mitigate exclusion and maintain data integrity, and ICON’s expertise enhances that capability.”

Izotropic Corp. is the only publicly traded company commercializing a dedicated breast CT imaging platform for the more accurate detection and diagnosis of breast cancers.

Izotropic (IZO) is up 7.69 per cent, trading at C$0.42 at 11:45 am ET.

More From The Market Herald
Medicenna - President and CEO, Fahar Merchant.

" Medicenna (TSX:MDNA) closes US$20 million public offering

Medicenna Therapeutics Corp. (MDNA) has closed its

" Titan Medical (TSX:TMD) reports Q2 2022 financial results

Titan Medical (TMD) released financial results for the three and six months ended June 30, 2022.

" Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023

Aleafia Health (AH) reported its financial results for the three months ended June 30, 2022.

" UniDoc (CSE:UDOC) signs agreement to provide telehealth services in Kenya

UniDoc Health (UDOC) has signed a master equipment deployment and services agreement with Claron Health to provide telehealth services in Kenya.